The GLOW stack: a combination needs its own evidence
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

GLOW usually refers to a blend of GHK-Cu, BPC-157 and a product called TB-500. Listing three mechanisms does not test the mixture. GHK-Cu has cell-culture research. BPC-157 has tendon and injury experiments. TB-500 also has naming problems: evidence on full-length thymosin beta-four cannot simply be reassigned to a fragment. Combining substances introduces new questions about interactions, stability and safety. Separate ingredient studies cannot show that the blend improves skin or recovery in people. For an evidence-led explanation, ask for the exact formulation and controlled human outcomes. A memorable stack name is not a clinical result.

END CARD
Evidence first. Educational only. Sources in description.

SOURCES
[1] Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex GHK-Cu
https://pubmed.ncbi.nlm.nih.gov/3169264/
Primary cell-culture study

[2] The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
https://pubmed.ncbi.nlm.nih.gov/21030672/
Primary rat tendon explant and tendon-cell study

[3] FDA Pharmacy Compounding Advisory Committee briefing: TB-500-related bulk drug substances
https://www.fda.gov/media/193349/download
US regulator technical identity and evidence assessment; July 2026

[4] FDA: Certain bulk drug substances that may present significant safety risks
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
US regulator; route-specific safety assessment, not a universal ban or approval list

EVIDENCE LIMITATIONS
GLOW is not a standardized scientific formulation in these sources.
Never state that the combination is synergistic, safer, or superior to its components.
Do not merge full-length thymosin beta-four and TB-500-fragment data.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/941529288799777/